210 related articles for article (PubMed ID: 27141403)
1. MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition.
David JM; Hamilton DH; Palena C
Oncoimmunology; 2016 Apr; 5(4):e1117738. PubMed ID: 27141403
[TBL] [Abstract][Full Text] [Related]
2. Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack.
Hamilton DH; McCampbell KK; Palena C
Front Oncol; 2018; 8():143. PubMed ID: 29774202
[TBL] [Abstract][Full Text] [Related]
3. WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition.
Hamilton DH; Huang B; Fernando RI; Tsang KY; Palena C
Cancer Res; 2014 May; 74(9):2510-9. PubMed ID: 24626094
[TBL] [Abstract][Full Text] [Related]
4. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells.
Fernando RI; Litzinger M; Trono P; Hamilton DH; Schlom J; Palena C
J Clin Invest; 2010 Feb; 120(2):533-44. PubMed ID: 20071775
[TBL] [Abstract][Full Text] [Related]
5. Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.
Roselli M; Fernando RI; Guadagni F; Spila A; Alessandroni J; Palmirotta R; Costarelli L; Litzinger M; Hamilton D; Huang B; Tucker J; Tsang KY; Schlom J; Palena C
Clin Cancer Res; 2012 Jul; 18(14):3868-79. PubMed ID: 22611028
[TBL] [Abstract][Full Text] [Related]
6. Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition.
Hamilton DH; David JM; Dominguez C; Palena C
Cells Tissues Organs; 2017; 203(2):128-138. PubMed ID: 28214895
[TBL] [Abstract][Full Text] [Related]
7. Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers.
Song W; Gobe GC
Curr Cancer Drug Targets; 2016; 16(7):586-93. PubMed ID: 27018266
[TBL] [Abstract][Full Text] [Related]
8. Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas.
Hamilton DH; Litzinger MT; Fernando RI; Huang B; Palena C
Semin Oncol; 2012 Jun; 39(3):358-66. PubMed ID: 22595058
[TBL] [Abstract][Full Text] [Related]
9. Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer.
Zhang L; Ma T; Brozick J; Babalola K; Budiu R; Tseng G; Vlad AM
Oncogene; 2016 Sep; 35(38):5010-20. PubMed ID: 26973247
[TBL] [Abstract][Full Text] [Related]
10. Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines.
Palena C; Hamilton DH
Adv Cancer Res; 2015; 128():69-93. PubMed ID: 26216630
[TBL] [Abstract][Full Text] [Related]
11. The potential role of Brachyury in inducing epithelial-to-mesenchymal transition (EMT) and HIF-1α expression in breast cancer cells.
Shao C; Zhang J; Fu J; Ling F
Biochem Biophys Res Commun; 2015 Nov; 467(4):1083-9. PubMed ID: 26393908
[TBL] [Abstract][Full Text] [Related]
12. Transfection of T-Box Transcription Factor
Akimoto N; Nakamura K; Hijioka H; Kume K; Matsumura Y; Sugiura T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30453543
[TBL] [Abstract][Full Text] [Related]
13. The T-box transcription factor Brachyury promotes renal interstitial fibrosis by repressing E-cadherin expression.
Sun S; Sun W; Xia L; Liu L; Du R; He L; Li R; Wang H; Huang C
Cell Commun Signal; 2014 Nov; 12():76. PubMed ID: 25433496
[TBL] [Abstract][Full Text] [Related]
14. Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.
Hamilton DH; Litzinger MT; Jales A; Huang B; Fernando RI; Hodge JW; Ardiani A; Apelian D; Schlom J; Palena C
Oncotarget; 2013 Oct; 4(10):1777-90. PubMed ID: 24125763
[TBL] [Abstract][Full Text] [Related]
15. Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity.
Ye J; Wei X; Shang Y; Pan Q; Yang M; Tian Y; He Y; Peng Z; Chen L; Chen W; Wang R
Oncogene; 2017 Nov; 36(46):6391-6407. PubMed ID: 28745318
[TBL] [Abstract][Full Text] [Related]
16. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy.
Palena C; Polev DE; Tsang KY; Fernando RI; Litzinger M; Krukovskaya LL; Baranova AV; Kozlov AP; Schlom J
Clin Cancer Res; 2007 Apr; 13(8):2471-8. PubMed ID: 17438107
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of Expression of the Epithelial-Mesenchymal Transition-Related Factor Brachyury in Intrathoracic Lymphatic Spread of Non-Small Cell Lung Cancer.
Shimamatsu S; Okamoto T; Haro A; Kitahara H; Kohno M; Morodomi Y; Tagawa T; Okano S; Oda Y; Maehara Y
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):1012-1020. PubMed ID: 27600618
[TBL] [Abstract][Full Text] [Related]
18. The Roles of Embryonic Transcription Factor BRACHYURY in Tumorigenesis and Progression.
Chen M; Wu Y; Zhang H; Li S; Zhou J; Shen J
Front Oncol; 2020; 10():961. PubMed ID: 32695672
[TBL] [Abstract][Full Text] [Related]
19. Regulation of brachyury by fibroblast growth factor receptor 1 in lung cancer.
Hu Y; Feng X; Mintz A; Petty WJ; Hsu W
Oncotarget; 2016 Dec; 7(52):87124-87135. PubMed ID: 27893433
[TBL] [Abstract][Full Text] [Related]
20. Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer.
Hata T; Rajabi H; Yamamoto M; Jin C; Ahmad R; Zhang Y; Kui L; Li W; Yasumizu Y; Hong D; Miyo M; Hiraki M; Maeda T; Suzuki Y; Takahashi H; Samur M; Kufe D
Mol Cancer Ther; 2019 Oct; 18(10):1744-1754. PubMed ID: 31308076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
